Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Patent number: 10064927
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 4, 2018
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • Publication number: 20180215709
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Application
    Filed: March 16, 2015
    Publication date: August 2, 2018
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard LERER, Mugesh GOVINDASAMY, Tzuri LIFSCHYTZ
  • Publication number: 20180216064
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Orna SINGER
  • Patent number: 10033106
    Abstract: A transdermal antenna may be partially inserted into a cavity in the body of a mammal to receive wireless data transmissions from devices located within the body and relay the data to devices located outside of the body. The transdermal antenna may include a first antenna which may be inserted inside of the body cavity and receive radio frequency data transmissions from devices located inside the body. The transdermal antenna may conduct the received data transmissions to a relay mechanism located outside of the body using coaxial cables, waveguides or a combination of both. The relay mechanism may relay the conducted data transmissions to a receiver device located outside of the body by using a wire connection, such as a coaxial cable, or a wireless communication link via a transceiver coupled to a second antenna.
    Type: Grant
    Filed: October 3, 2010
    Date of Patent: July 24, 2018
    Assignee: Hadasit Medical Research Services & Development Ltd.
    Inventors: Noam Livneh, Yoav Mintz, Vered Bar-Bracha, Arik Bracha
  • Publication number: 20180200324
    Abstract: The present invention discloses a peptide capable of stabilizing mutation-induced GBE1 protein destabilization, conjugates comprising same and uses thereof for the treatment of diseases and disorders associate with glycogen storage.
    Type: Application
    Filed: July 21, 2016
    Publication date: July 19, 2018
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Or KAKHLON, Amit MICHAELI
  • Patent number: 10000549
    Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: June 19, 2018
    Assignees: KAHR Medical Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventor: Michal Dranitzki Elhalel
  • Patent number: 9993497
    Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: June 12, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'acov
  • Patent number: 9981037
    Abstract: The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, ?-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with ?-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: May 29, 2018
    Assignees: The Brigham and Women's Hospital, Inc., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron Ilan, Howard L. Weiner
  • Publication number: 20180134752
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Application
    Filed: August 21, 2017
    Publication date: May 17, 2018
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rachel BAR-SHAVIT
  • Patent number: 9957314
    Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: May 1, 2018
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Dan Deutsch, Amir Haze, Anat Blumenfeld
  • Publication number: 20180111989
    Abstract: Provided is a method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction. Also provided are compositions including the agent.
    Type: Application
    Filed: March 31, 2016
    Publication date: April 26, 2018
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Patent number: 9944988
    Abstract: The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an NLGn4 gene product in the immune cell population using NLGn4 specific primers or NLGn4 specific probes.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: April 17, 2018
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • Publication number: 20180099006
    Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.
    Type: Application
    Filed: December 11, 2017
    Publication date: April 12, 2018
    Applicants: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar COHEN, Yaron ILAN, Eyal SHTEYER, Ami BEN-YA'ACOV
  • Publication number: 20180085347
    Abstract: Cyclic nitroxide compounds including, but not limited to, compounds having the general formula I: wherein the dashed line and R1-R8 are as defined herein, are disclosed herein for use in treating diseases and disorders of the respiratory tract and/or respiratory tract remodeling.
    Type: Application
    Filed: March 24, 2016
    Publication date: March 29, 2018
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.
    Inventors: Sara GOLDSTEIN, Amram SAMUNI, Neville BERKMAN
  • Patent number: 9877806
    Abstract: The present invention provides an article, at least part of it being coated by inorganic fullerene-like (IF) nanoparticles or composite containing such nanoparticles. Preferably, the invention provides an article made of metal, for use in dentistry or medicine e.g. archwire, needle or catheter, having a friction-reducing film, and methods for coating such articles with a friction-reducing film.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: January 30, 2018
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., HADASIT MEDICAL RESEARCH SERVICE AND DEVELOPMENT LTD., HOLON ACADEMIC INSTITUTE OF TECHNOLOGY
    Inventors: Reshef Tenne, Alon Katz, Meir Redlich, Lev Rapoport
  • Patent number: 9797911
    Abstract: An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed.
    Type: Grant
    Filed: June 15, 2014
    Date of Patent: October 24, 2017
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Eli Keshet, Shay Sela, Ahuva Itin, Simcha Yagel
  • Patent number: 9745347
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: August 29, 2017
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rachel Bar-Shavit
  • Publication number: 20170199190
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Application
    Filed: March 28, 2017
    Publication date: July 13, 2017
    Applicants: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Nurit YACHIMOVICH-COHEN, Limor MATZRAFI
  • Patent number: 9669136
    Abstract: The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: June 6, 2017
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Michael Friedman, Yoel Sasson, Ada Grin, Rami Mosheiff, Jacob Rachmilewitz
  • Patent number: 9658216
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: May 23, 2017
    Assignees: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Nurit Yachimovich-Cohen, Limor Matzrafi